Oak Ridge Investments LLC Trims Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Oak Ridge Investments LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,220 shares of the biopharmaceutical company’s stock after selling 2,120 shares during the period. Oak Ridge Investments LLC’s holdings in Halozyme Therapeutics were worth $2,783,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Verdence Capital Advisors LLC boosted its holdings in Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 252 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the period. Juncture Wealth Strategies LLC increased its stake in shares of Halozyme Therapeutics by 3.6% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock valued at $690,000 after purchasing an additional 415 shares in the last quarter. Diversify Advisory Services LLC raised its holdings in Halozyme Therapeutics by 8.5% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 418 shares during the period. Finally, Sheaff Brock Investment Advisors LLC boosted its position in Halozyme Therapeutics by 7.7% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 507 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 1.0 %

NASDAQ HALO opened at $54.80 on Friday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The business’s fifty day simple moving average is $49.62 and its 200-day simple moving average is $54.11. The firm has a market cap of $6.97 billion, a PE ratio of 18.15, a P/E/G ratio of 0.40 and a beta of 1.24.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HALO. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday, January 10th. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.